2012年7月
Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma
NUCLEAR MEDICINE COMMUNICATIONS
- 巻
- 33
- 号
- 7
- 開始ページ
- 719
- 終了ページ
- 725
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1097/MNM.0b013e3283531d68
- 出版者・発行元
- LIPPINCOTT WILLIAMS & WILKINS
Objective The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial cancers, including hepatocellular carcinoma (HCC), and is an attractive target for cancer imaging and therapy. We attempted a novel noninvasive imaging method to evaluate anti-EGFR human monoclonal antibody clones for determining the uptake of therapeutic anti-EGFR antibody in HCC.
Methods In-vitro cell binding of nine I-125-labeled antibody clones was compared in the human epidermoid cancer cell line A431, in three HCC cell lines Hep-G2, SK-Hep1, and HuH-7, and in the EGFR-negative control cell line A4. In-111-labeled or I-125-labeled 048-006 was subjected to cell binding, competitive inhibition, and internalization assays using A431, SK-Hep1, and HuH-7. Further, In-111-labeled 048-006 was evaluated in in-vivo biodistribution analysis and single-photon imaging in nude tumor-bearing mice.
Results The 048-006 clone showed the highest binding to EGFR-expressing cells among the nine antibodies. In-111-labeled or I-125-labeled 048-006 specifically bound to EGFR-expressing cells with high affinity and was internalized after binding to EGFR. A431 and HuH-7 tumors showed high In-111-labeled 048-006 uptake, which was visualized by single-photon imaging.
Conclusion Radiolabeled human anti-EGFR monoclonal antibody 048-006 has the potential to be a safer imaging probe for predicting tumor uptake of anti-EGFR antibody therapeutic agents in HCC. Nucl Med Commun 33:719-725 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Methods In-vitro cell binding of nine I-125-labeled antibody clones was compared in the human epidermoid cancer cell line A431, in three HCC cell lines Hep-G2, SK-Hep1, and HuH-7, and in the EGFR-negative control cell line A4. In-111-labeled or I-125-labeled 048-006 was subjected to cell binding, competitive inhibition, and internalization assays using A431, SK-Hep1, and HuH-7. Further, In-111-labeled 048-006 was evaluated in in-vivo biodistribution analysis and single-photon imaging in nude tumor-bearing mice.
Results The 048-006 clone showed the highest binding to EGFR-expressing cells among the nine antibodies. In-111-labeled or I-125-labeled 048-006 specifically bound to EGFR-expressing cells with high affinity and was internalized after binding to EGFR. A431 and HuH-7 tumors showed high In-111-labeled 048-006 uptake, which was visualized by single-photon imaging.
Conclusion Radiolabeled human anti-EGFR monoclonal antibody 048-006 has the potential to be a safer imaging probe for predicting tumor uptake of anti-EGFR antibody therapeutic agents in HCC. Nucl Med Commun 33:719-725 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
- リンク情報
- ID情報
-
- DOI : 10.1097/MNM.0b013e3283531d68
- ISSN : 0143-3636
- Web of Science ID : WOS:000305500600006